参考文献/References:
[1]Jackson LR 2 nd,Rathakrishnan B,Campbell K,et al. Sinus node dysfunction and atrial fibrillation:a reversible phenomenon?[J]. Pacing Clin Electrophysiol,2017,40(4):442-450.
[2]袁朝汉,张焕基,伍贵富. 心房颤动发生及维持机制研究新进展[J]. 心血管病学进展,2017,38(5):520-522.
[3]Ku? J,Stallmeyer B,Goldstein M,et al. Familial sinus node disease caused by a gain of GIRK(G-Protein Activated InwardlyRectifying K+ Channel) channel function[J]. Circ Genom Precis Med,2019,12(1):e002238.
[4]Hayashi H,Sumiyoshi M,Nakazato Y,et al. Brugada syndrome and sinus node dysfunction[J]. J Arrhythm,2018,34(3) :216-221.
[5]de Ponti R,Marazzato J,Bagliani G,et al. Sick sinus syndrome[J]. Card Electrophysiol Clin,2018,10(2):183-195.
[6]Burstein B,Nattel S. Atrial fibrosis:mechanisms and clinical relevance in atrial fibrillation[J]. J Am Coll Cardiol,2008,51(8):802-809.
[7]Korantzopoulos P,Letsas KP,Tse G,et al. Inflammation and atrial fibrillation:a comprehensive review[J]. J Arrhythm,2018,34 (4):394-401.
[8]Jackson LR 2nd,Rathakrishnan B,Campbell K,et al. Sinus node dysfunction and atrial fibrillation:a reversible phenomenon?[J]. Pacing Clin Electrophysiol,2017,40(4):442-450.
[9]Nattel S. Molecular and cellular mechanisms of atrial fibrosis in atrial fibrillation[J]. JACC Clin Electrophysiol,2017,3(5):425-435.
[10]Thanigaimani S,Lau DH,Agbaedeng T,et al. Molecular mechanisms of atrial fibrosis:implications for the clinic[J]. Expert Rev Cardiovasc Ther,2017,15(4):247-256.
[11]Huang GY,Peng Z,Zhan Y,et al. Relationship between the change in pacing threshold and the myocardial injury[J]. Eur Rev Med Pharmacol Sci,2017,21(24):5774-5780.
[12]Bellmann B,Roser M,Muntean B,et al. Atrial standstill in sinus node disease due to extensive atrial fibrosis:impact on dual chamber pacemaker implantation[J]. Europace,2016,18(2):238-245.
[13]Benito EM,de Luna AB,Baranchuk A,et al. Extensive atrial fibrosis assessed by late gadolinium enhancement cardiovascular magnetic resonance associated with advanced interatrial block electrocardiogram pattern[J]. Europace,2017,19(3):377-377.
[14]马新欣,张跃力. 超声心动图评价左心房重构的应用[J]. 中国医学影像技术,2015,31(12):1915-1918.
[15]Wang GD,Shen LH,Wang L,et al. Relationship between integrated backscatter and atrial fibrosis in patients with and without atrial fibrillation who are undergoing coronary bypass surgery[J]. Clin Cardiol,2009,32(9):E56-E61.
[16]Cameli M,Lisi M,Righini FM,et al. Usefulness of atrial deformation analysis to predict left atrial fibrosis and endocardial thickness in patients undergoing mitral valve operations for severe mitral regurgitation secondary to mitral valve prolapse[J]. Am J Cardiol,2013,111(4):595-601.
[17]Fu X,Kassim SY,Parks WC,et al. Hypochlorous acid generated by myeloperoxidase modifies adjacent tryptophan and glycine residues in the catalytic domain of matrix metalloproteinase-7(matrilysin):an oxidative mechanism for restraining proteolytic activity during inflammation[J]. J Biol Chem,2003,278(31):28403-28409.
[18]Rudolph V,Andrié RP,Rudolph TK,et al. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation[J]. Nat Med,2010,16(4):470-474.
[19]Weymann A,Popov AF,Sabashnikov A,et al. Baseline and postoperative levels of C-reactive protein and interleukins as inflammatory predictors of atrial fibrillation following cardiac surgery:a systematic review and meta-analysis[J]. Kardiol Pol,2018,76(2):440-451.
[20]Scott L,Li N,Dobrev D. Role of inflammatory signaling in atrial fibrillation[J]. Int J Cardiol,2019,287:195-200.
[21]Karam BS,Chavez-Moreno A,Koh W,et al. Oxidative stress and inflammation as central mediators of atrial fibrillation in obesity and diabetes[J]. Cardiovasc Diabetol,2017,16(1):120.
[22]Liu L,Wu L,Zheng L,et al. Associations between multiple circulating biomarkers and the presence of atrial fibrillation in hypertrophic cardiomyopathy with or without left ventricular outflow tract obstruction[J]. Int Heart J,2019,60(2):327-335.
[23]曹哲哲,马瑞彦. 心房颤动的心房纤维化分子机制研究进展[J]. 心血管病学进展,2019,40(3):359-362.
[24]Kim N,Jung Y,Nam M,et al. AngiotensinⅡaffects inflammation mechanisms via AMPK-related signalling pathways in HL-1 atrial myocytes[J]. Sci Rep,2017,7(1):10328.
[25]Tadevosyan A,Xiao J,Surinkaew S,et al. Intracellular angiotensin-Ⅱinteracts with nuclear angiotensin receptors in cardiac fibroblasts and regulates RNA synthesis,cell proliferation,and collagen secretion[J]. J Am Heart Assoc,2017,6(4):e004965.
[26]王燕,许纲,程立君,等. 心房纤维化研究进展[J]. 心血管病学进展,2019,40(3):389-392.
[27]Jansen HJ,Mackasey M,Moghtadaei M,et al. Distinct patterns of atrial electrical and structural remodeling in angiotensinⅡ mediated atrial fibrillation[J]. J Mol Cell Cardiol,2018,124:12-25.
[28]Walters TE,Kalman JM,Patel SK,et al. Angiotensin converting enzyme 2 activity and human atrial fibrillation:increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling[J]. Europace,2017,19(8):1280-1287.
[29]Kerkel R,Ulvila J,Magga J. Natriuretic peptides in the regulation of cardiovascular physiology and metabolic events[J]. J Am Heart Assoc,2015,4(10):e002423.
[30]Tsai YT,Lin FY,Lin CS,et al. B-type natriuretic peptide enhances fibrotic effects via matrix metalloproteinase-2 expression in the mouse atrium in vivo and in human atrial myofibroblasts in vitro[J]. Transl Res,2019,208:30-46.
[31]Nattel S. Natriuretic protein receptors and atrial selective fibrosis:potential role in atrial fibrillation[J]. Cardiovasc Res,2019,115(2):258-260.